Results 161 to 170 of about 132,138 (294)

S. aureus colonization and clinical symptoms remain stable upon topical XZ.700 treatment: Results of a double‐blind randomized clinical trial in patients with mild to moderate atopic dermatitis

British Journal of Clinical Pharmacology, EarlyView.
Aim Recovering dysbiosis may improve atopic dermatitis (AD) symptoms. XZ.700 is a recombinant chimeric endolysin that specifically targets Staphylococcus aureus and could be a new treatment option for patients with AD. The aim of this first‐in‐human study was to evaluate the safety, tolerability and efficacy of topical XZ.700 and explore the ...
Laura W. J. van der Meulen, Menthe E. Bergmans, Salma Assil, Naomi Klarenbeek, Marieke L. de Kam, Alexa J. Tibboel, Thorsten Brach, Bjorn L. Herpers, Johan Frieling, Vincent de Jong, Benthe Freyee, Martijn B. A. van Doorn, Robert Rissmann, Tessa Niemeyer–van der Kolk   +13 more
wiley   +1 more source

Eudragit®‐engineered pH‐responsive probiotic microspheres with enhanced gastrointestinal resistance and prolonged storage stability for inflammatory bowel disease therapy

BMEMat, EarlyView.
This study reports the development of AMS@Eud core‐shell microspheres, combining calcium alginate and pH‐responsive Eudragit® L100, which exhibit exceptional gastrointestinal resistance and long‐term storage stability (only 5.28%–9.09% viability loss over 35 days at 4–25°C), and effectively alleviate inflammatory bowel disease via gut microbiota ...
Ming Teng, Xiaomin Luo, Peng Zhang, Chen Yang, Yuniel Ma, Xinhua Liu   +5 more
wiley   +1 more source

Controllable engineered probiotic microspheres for treating ulcerative colitis: A cascade enzyme‐catalyzed strategy to restore intestinal redox homeostasis

BMEMat, EarlyView.
A dual strategy integrating genetic engineering and physical encapsulation was proposed to enhance the cell viability and antioxidant properties of probiotics. The cascade antioxidant enzymes released from probiotic microspheres restore intestinal redox homeostasis by eliminating intestinal reactive oxygen species for ulcerative colitis treatment ...
Xiaolong Mao, Xiangwei Lv, Miaomiao Zhang, Jiayi Liu, Yun Chen, Yunna Li, Gaoyuan Liu, Fuming Yang, Ziqiang Han, Yunyun Wei   +9 more
wiley   +1 more source

Maternal Oral Microbiome Dysbiosis and Adverse Pregnancy Outcomes: Microbial Signatures, Inflammatory Pathways, and Clinical Evidence. [PDF]

J Clin Med
Radu EA, Mocanu E, Fulina M, Rotar V, Enache F, Popescu S, Șerbănescu L.   +6 more
europepmc   +1 more source

The ageing holobiont: crosstalk between telomere dynamics, oxidative stress and the gut microbiome

Biological Reviews, EarlyView.
ABSTRACT The gut tissue is at the frontline of early onset of ageing. It exhibits high cell turnover rates and rapid telomere shortening, which can have systemic effects on the developing or senescing organism. We conducted a literature review of studies on the crosstalk between telomere length dynamics, telomerase activity, oxidative stress, and gut ...
Michael L. Pepke, Søren B. Hansen, Morten T. Limborg   +2 more
wiley   +1 more source

The role of gut dysbiosis in endocrine and metabolic derangements of chronic kidney disease: mechanisms, controversies, and future perspectives. [PDF]

Front Endocrinol (Lausanne)
Ouyang Z, Hu W, Zhu F, Zhang Y, Wang L, Ye Q.   +5 more
europepmc   +1 more source

Living Microbial Drugs

Chemistry – A European Journal, EarlyView.
The introduction outlines the review scope. Microbial cell factories as living drugs cover host–gut microbiota, bacteria, yeast, and other microbial systems, with comparative host advantages. Engineering strategies include synthetic circuits, quorum sensing, and memory.
Cemile Elif Özçelik, Nazlıcan Tunç, Senem Şen, Urartu Özgür Şafak Şeker   +3 more
wiley   +1 more source

Progress on the correlation between sepsis and gut microbiota: a narrative review. [PDF]

Front Microbiol
Yuan Y, Li J, Yang C.
europepmc   +1 more source

From Inflammatory Bowel Disease to Cancer: Gut Microbiota–Immune Microenvironment Crosstalk and Natural Product‐Based Therapeutic Opportunities

Cancer Nexus, EarlyView.
ABSTRACT Inflammatory bowel disease (IBD), primarily Crohn's disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract and an important risk factor for IBD‐associated cancer. Increasing evidence suggests that gut microbiota dysbiosis, epithelial barrier dysfunction, and immune microenvironment remodeling
Xue Zhang, Chongchong Gao, Rui Jiang, Zijian Wu, Jian Bai   +4 more
wiley   +1 more source

Editorial: Deciphering the microbiome's role in the progression of interstitial lung diseases. [PDF]

Front Med (Lausanne)
Carbone RG, Russell AM.
europepmc   +1 more source